"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
4:58
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Breast Cancer
"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Breast Cancer Similar Videos
Similar Videos
-
Manali Bhave, MD; Emory University Winship Cancer Institute; #DDHO2022
15:09
-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: Leveraging Antibody-Drug Conjugates in Breast Cancer Care_Hope Rugo, MD, FASCO
53:15
-
Cletus Arciero, MD; Emory University Winship Cancer Institute; #DDHO2022
19:22
